Ergoteles’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Ergoteles’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,181	Closed	-$65.3K	–	1848
2022 Q4	$65.3K	Buy	+18,181	New	+$78.9K	﹤0.01%	1268
2022 Q3	–	Sell	-26,940	Closed	-$259K	–	2077
2022 Q2	$259K	Buy	+26,940	New	+$252K	0.01%	1189

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Ergoteles's SYRS Position: Q1 2023 in Review

Ergoteles sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2023, closing a stake of 18,181 shares — an estimated $65.3K sold.

Ergoteles first reported a position in SYRS in Q2 2022 and held it in 2 quarters. The position peaked at $259K in Q2 2022. 59 funds tracked by Wall St. Rank hold SYRS as of Q1 2023.

Ergoteles reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 18,181 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $65.3K.
Ergoteles first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
Ergoteles's Syros Pharmaceuticals, Inc. Common Stock position peaked at $259K in Q2 2022.
59 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.